Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Ablynx NV currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, SZPERKA, MICHAEL EDWARD, who is the busiest examiner with 1 busiest examiner pending office action. This indicates a very focused prosecution profile with a single point of contact at the patent office. The prosecution is limited to 1 distinct art unit.
For a practitioner, this means that the 1 distinct examiner has total control over the current pending matter. There is no diversity in the portfolio to provide alternative prosecution paths or to mitigate the impact of a single examiner's perspective. With only 1 pending office action, the company's immediate workload is minimal. The practitioner should focus on the specific examination style of SZPERKA, MICHAEL EDWARD within the 1 distinct art unit to successfully navigate this 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SZPERKA, MICHAEL EDWARD | 1 | 62.9% | +36.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18482187 | POLYPEPTIDES BINDING ADAMTS5, MMP13 AND AGGRECAN | SZPERKA, MICHAEL EDWARD | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18482187 | POLYPEPTIDES BINDING ADAMTS5, MMP13 AND AGGRECAN | SZPERKA, MICHAEL EDWARD | 1641 | §103§112DP | Non-Final OA | — | Pending | Oct 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial